Analysis of U.S. Patent 5,714,520: Scope, Claims, and Patent Landscape
What does U.S. Patent 5,714,520 cover?
U.S. Patent 5,714,520, granted on February 3, 1998, to Eli Lilly and Company, protects a composition comprising a substituted pyrazole derivative. The patent claims the compound's use as a pharmaceutical agent, specifically targeting the inhibition of enzymes such as phosphodiesterases (PDEs). The patent emphasizes the utility of these compounds in treating cardiovascular, respiratory, and immunological disorders.
Key compounds and structural features:
- The patent includes multiple substituted pyrazole derivatives.
- General formula: A pyrazole ring with various substitutions at specific positions.
- The chemical claims focus on substituents that confer PDE inhibitory activity.
What are the primary claims?
U.S. Patent 5,714,520 includes 14 claims, with the core being:
- Claim 1: A compound with a specific chemical structure, characterized by particular substituents on the pyrazole ring, which exhibits PDE inhibitory activity.
- Claim 2-14: Dependent claims specify particular substitutions, such as methyl, ethyl, or halogen groups, enhancing activity or selectivity.
Scope of claims:
- The claims cover both broad classes of substituted pyrazoles and specific compounds.
- They encompass both free base and pharmacologically acceptable salt forms.
- The claims extend to pharmaceutical compositions containing these compounds and methods of use in treating diseases characterized by abnormal PDE activity.
How broad is the patent's scope?
The patent's scope is relatively broad in chemical structure but specific in the target activity and therapeutic applications:
| Aspect |
Details |
| Chemical scope |
Includes a range of substituted pyrazoles with variations at key positions, covering multiple derivatives. |
| Therapeutic scope |
Encompasses PDE inhibitors for diverse indications like COPD, asthma, cardiovascular diseases, and neurological disorders. |
| Formulation |
Claims the use in pharmaceutical compositions, including salts, esters, and prodrugs. |
This breadth allows the patent holder to potentially cover numerous derivatives and therapeutic uses within the chemical class.
Patent landscape context
Related patents and prior art:
- The patent references prior art related to PDE inhibitors, especially selective PDE4 inhibitors developed in the early 1990s.
- It overlaps with subsequent patents on pyrazole derivatives in the PDE inhibitor class, notably those filed by other pharmaceutical companies targeting similar indications.
Key competitors and subsequent patents:
- Companies like GlaxoSmithKline (GSK), Pfizer, and Sanofi have filed patents on PDE4 inhibitors with similar chemical backbones.
- For example, GSK's patent WO1999067780 claims structurally related compounds in the same class.
- The landscape is characterized by overlapping claims on chemical structure and therapeutic applications, creating potential patent thickets.
Patent expiration:
- U.S. Patent 5,714,520 has a typical 20-year term from the filing date (September 24, 1996), expiring in September 2016.
- Since the patent is expired, it no longer provides exclusivity for the claimed compounds.
Implications for R&D and Intellectual Property Strategies
The expiration opens the field for generic development. Active research continues on similar pyrazole-based PDE inhibitors with improved selectivity and pharmacokinetics.
Newer patents focus on:
- Improving selectivity for PDE4 over other PDE classes.
- Reducing side effects associated with PDE4 inhibition.
- Developing prodrugs or formulations with enhanced bioavailability.
Summary
U.S. Patent 5,714,520 protects a class of substituted pyrazole PDE inhibitors, with claims covering a broad chemical scope and multiple therapeutic indications. Its expiration in 2016 shifts industry dynamics, allowing competitors to pursue further innovations or generic equivalents. The patent landscape is dense, characterized by overlapping claims and ongoing innovations targeting specific PDE isoforms.
Key Takeaways
- The patent broadly covers substituted pyrazoles as PDE inhibitors for multiple indications.
- Its expiration in 2016 enables generic development and competition.
- The patent landscape includes overlapping patents focusing on PDE4 and related inhibitors.
- Companies continue to innovate on selectivity, delivery, and safety profiles in this class.
- Strategic patenting focuses on narrower claims, formulations, and specific indications post-expiration.
FAQs
1. What is the significance of the claims' breadth in U.S. Patent 5,714,520?
It allows coverage of a wide range of derivatives within the chemical class, supporting broad rights but also increasing risk of patent challenge.
2. Could competitors patent derivatives of the compounds disclosed?
Yes, if the derivatives are sufficiently novel, non-obvious, and non-infringing, new patents can be filed.
3. How do subsequent filings relate to this patent?
Later patents often focus on improving selectivity, pharmacokinetics, or reducing side effects within the chemical class covered.
4. Does the expiration impact ongoing research?
Yes, once expired, generic companies can produce similar compounds without infringing this patent, increasing market competition.
5. Are there known legal challenges to this patent?
No significant patent oppositions are publicly documented; however, its narrow or broad claims could be contested in litigation or patent office reexaminations.
References
[1] United States Patent and Trademark Office. (1996). Patent Application Serial No. 08/713,897.
[2] GSK Patent WO1999067780. (1999).
[3] FDA’s Orange Book. (2022). List of approved drug products with therapeutic equivalence evaluations.
